{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:40Z","timestamp":1787019580013,"version":"build-2736575974"},"reference-count":33,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["Study identifier: 212821"],"award-info":[{"award-number":["Study identifier: 212821"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2023,1,3]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An objective of the Severe Heterogeneous Asthma Registry, Patient-centered (SHARP) is to produce real-world evidence on a pan-European scale by linking nonstandardised, patient-level registry data. Mepolizumab has shown clinical efficacy in randomised controlled trials and prospective real-world studies and could therefore serve as a proof of principle for this novel approach. The aim of the present study was to harmonise data from 10 national severe asthma registries and characterise patients receiving mepolizumab, assess its effectiveness on annual exacerbations and maintenance oral glucocorticoid (OCS) use, and evaluate treatment patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this observational cohort study, registry data (5871 patients) were extracted for harmonisation. Where harmonisation was possible, patients who initiated mepolizumab between 1 January 2016 and 31 December 2021 were examined. Changes of a 12-month (range 11\u201318\u2005months) period in frequent (two or more) exacerbations, maintenance OCS use and dose were analysed in a privacy-preserving manner using meta-analysis of generalised estimating equation parameters. Periods before and during the coronavirus disease 2019 pandemic were analysed separately.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 912 patients who fulfilled selection criteria, mepolizumab significantly reduced frequent exacerbations (OR 0.18, 95% CI 0.13\u20130.25), maintenance OCS use (OR 0.75, 95% CI 0.61\u20130.92) and dose (mean \u22123.93\u2005mg\u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      , 95% CI \u22125.24\u20132.62 mg\u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      ) in the pre-pandemic group, with similar trends in the pandemic group. Marked heterogeneity was observed between registries in patient characteristics and mepolizumab treatment patterns.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>By harmonising patient-level registry data and applying federated analysis, SHARP demonstrated the real-world effectiveness of mepolizumab on asthma exacerbations and maintenance OCS use in severe asthma patients across Europe, consistent with previous evidence. This paves the way for future pan-European real-world severe asthma studies using patient-level data in a privacy-proof manner.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00745-2022","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T11:45:18Z","timestamp":1678362318000},"page":"00745-2022","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis"],"prefix":"10.1183","volume":"9","author":[{"given":"Johannes A.","family":"Kroes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alfonso-Cristancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna T.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Berret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Bieksiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5209","authenticated-orcid":false,"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Brussino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Canhoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulfem","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Csoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbro","family":"Dahl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"Damadoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9628-2174","authenticated-orcid":false,"given":"Katrien","family":"Eger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Gauquelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5953-4881","authenticated-orcid":false,"given":"Bilun","family":"Gemicioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2060-689X","authenticated-orcid":false,"given":"Sophie","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik B.","family":"Hofstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0619-7927","authenticated-orcid":false,"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3837-8063","authenticated-orcid":false,"given":"Rupert W.","family":"Jakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1229-2181","authenticated-orcid":false,"given":"Fabienne","family":"Jaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginija","family":"Kalinauskaite-Zukauske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kopa\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namhee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0438-6126","authenticated-orcid":false,"given":"Claudia C.","family":"Loureiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Lozoya Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0909-0148","authenticated-orcid":false,"given":"Matthew","family":"Masoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Paula","family":"Rezelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"P\u00e9rez De Llano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Popovi\u0107-Grle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ramos-Barb\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"S\u00e0 Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Samitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2678-1373","authenticated-orcid":false,"given":"Florence","family":"Schleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Sirena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Skrgat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7436-4550","authenticated-orcid":false,"given":"Eleftherios","family":"Zervas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Zichnalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth H.","family":"Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob K.","family":"Sont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-3817","authenticated-orcid":false,"given":"Simone","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Ten Brinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"2024101710145446000_9.2.00745-2022.1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"2024101710145446000_9.2.00745-2022.2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/02770903.2016.1212371","article-title":"The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: a systematic review and meta-analysis","volume":"54","author":"Li","year":"2017","journal-title":"J Asthma"},{"key":"2024101710145446000_9.2.00745-2022.3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1080\/02770903.2017.1379534","article-title":"Efficacy and safety of benralizumab for eosinophilic asthma: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Tian","year":"2018","journal-title":"J Asthma"},{"key":"2024101710145446000_9.2.00745-2022.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01444-2018"},{"key":"2024101710145446000_9.2.00745-2022.5","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1016\/j.jaip.2020.04.029","article-title":"Treatment eligibility of real-life mepolizumab-treated severe asthma patients","volume":"8","author":"Richards","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101710145446000_9.2.00745-2022.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"2024101710145446000_9.2.00745-2022.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01163-2019"},{"key":"2024101710145446000_9.2.00745-2022.8","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0278-2021"},{"key":"2024101710145446000_9.2.00745-2022.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01671-2018"},{"key":"2024101710145446000_9.2.00745-2022.10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M18-2782","article-title":"Balancing protection and free movement of personal data: the new European Union general data protection regulation","volume":"170","author":"Bentzen","year":"2019","journal-title":"Ann Intern Med"},{"key":"2024101710145446000_9.2.00745-2022.11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12911-021-01602-x","article-title":"Privacy-preserving data sharing infrastructures for medical research: systematization and comparison","volume":"21","author":"Wirth","year":"2021","journal-title":"BMC Med Inform Decis Mak"},{"key":"2024101710145446000_9.2.00745-2022.12","unstructured":"Observational Health Data Sciences and Informatics . Standardized Data: the OMOP Common Data Model. 2022. www.ohdsi.org\/data-standardization\/the-common-data-model\/. Date last accessed: 24 January 2022."},{"key":"2024101710145446000_9.2.00745-2022.13","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00981-9"},{"key":"2024101710145446000_9.2.00745-2022.14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"2024101710145446000_9.2.00745-2022.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2024101710145446000_9.2.00745-2022.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2024101710145446000_9.2.00745-2022.17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024101710145446000_9.2.00745-2022.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2024101710145446000_9.2.00745-2022.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00151-2020"},{"key":"2024101710145446000_9.2.00745-2022.20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cea.13601","article-title":"Real-world experience with mepolizumab: does it deliver what it has promised?","volume":"50","author":"Schleich","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"2024101710145446000_9.2.00745-2022.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2024101710145446000_9.2.00745-2022.22","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00065-2022"},{"key":"2024101710145446000_9.2.00745-2022.23","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01434-3"},{"key":"2024101710145446000_9.2.00745-2022.24","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00168-2022"},{"key":"2024101710145446000_9.2.00745-2022.25","unstructured":"R Core Team . R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2021. www.R-project.org\/. Date last accessed: 25 May 2022."},{"key":"2024101710145446000_9.2.00745-2022.26","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.jaip.2021.01.028","article-title":"Mepolizumab and oral corticosteroid stewardship: data from the Australian Mepolizumab Registry","volume":"9","author":"Thomas","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101710145446000_9.2.00745-2022.27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2147\/JAA.S275944","article-title":"Real-world reductions in oral corticosteroid use in the USA following mepolizumab therapy for severe asthma","volume":"13","author":"Silver","year":"2020","journal-title":"J Asthma Allergy"},{"key":"2024101710145446000_9.2.00745-2022.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01313-2021"},{"key":"2024101710145446000_9.2.00745-2022.29","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI \u2013 a study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101710145446000_9.2.00745-2022.30","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/j.clinthera.2021.03.023","article-title":"Real-world effectiveness of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis","volume":"43","author":"Li","year":"2021","journal-title":"Clin Ther"},{"key":"2024101710145446000_9.2.00745-2022.31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024101710145446000_9.2.00745-2022.32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12931-022-01959-1","article-title":"Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma","volume":"23","author":"Korn","year":"2022","journal-title":"Respir Res"},{"key":"2024101710145446000_9.2.00745-2022.33","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma \u2013 a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00745-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:24:09Z","timestamp":1740356649000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00745-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4,3]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1183\/23120541.00745-2022"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00745-2022","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}